{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:41:32Z","timestamp":1790628092789,"version":"4.1.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40264-020-01010-6","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T10:02:37Z","timestamp":1603447357000},"page":"1211-1221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease"],"prefix":"10.1007","volume":"43","author":[{"given":"Tamara Y.","family":"Milder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard O.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-0973","authenticated-orcid":false,"given":"Jerry R.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"1010_CR1","doi-asserted-by":"publisher","unstructured":"Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D et al. US Renal Data System 2019 Annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020;75(1S1):A6\u2013A7. https:\/\/doi.org\/10.1053\/j.ajkd.2019.09.003.","DOI":"10.1053\/j.ajkd.2019.09.003"},{"issue":"7","key":"1010_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jdiacomp.2019.04.004","volume":"33","author":"M Branch","year":"2019","unstructured":"Branch M, German C, Bertoni A, Yeboah J. Incremental risk of cardiovascular disease and\/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial. J Diabetes Compl. 2019;33(7):468\u201372. https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.04.004.","journal-title":"J Diabetes Compl"},{"issue":"10","key":"1010_CR3","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"T Rieg","year":"2018","unstructured":"Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61(10):2079\u201386. https:\/\/doi.org\/10.1007\/s00125-018-4654-7.","journal-title":"Diabetologia"},{"issue":"22","key":"1010_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"4","key":"1010_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1515920.","journal-title":"N Engl J Med"},{"issue":"7","key":"1010_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"issue":"4","key":"1010_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"24","key":"1010_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"21","key":"1010_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"5","key":"1010_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1053\/j.ajkd.2019.05.009","volume":"74","author":"GL Bakris","year":"2019","unstructured":"Bakris GL. Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 Inhibitors. Am J Kidney Dis. 2019;74(5):573\u20135. https:\/\/doi.org\/10.1053\/j.ajkd.2019.05.009.","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"1010_CR11","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","volume":"138","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138(17):1904\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035759.","journal-title":"Circulation"},{"issue":"5","key":"1010_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2019.03.432","volume":"74","author":"ME Cooper","year":"2019","unstructured":"Cooper ME, Inzucchi SE, Zinman B, Hantel S, von Eynatten M, Wanner C, et al. Glucose control and the effect of empagliflozin on kidney outcomes in type 2 diabetes: an analysis from the EMPA-REG OUTCOME Trial. Am J Kidney Dis. 2019;74(5):713\u20135. https:\/\/doi.org\/10.1053\/j.ajkd.2019.03.432.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1010_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","volume":"141","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients With type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c\u2009<\u20097%: results from the CREDENCE trial. Circulation. 2020;141(5):407\u201310. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044359.","journal-title":"Circulation"},{"issue":"3","key":"1010_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.12182","volume":"16","author":"S Macha","year":"2014","unstructured":"Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16(3):215\u201322. https:\/\/doi.org\/10.1111\/dom.12182.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1010_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bcp.12056","volume":"76","author":"S Kasichayanula","year":"2013","unstructured":"Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76(3):432\u201344. https:\/\/doi.org\/10.1111\/bcp.12056.","journal-title":"Br J Clin Pharmacol"},{"key":"1010_CR16","doi-asserted-by":"publisher","unstructured":"Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D et al. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015;37(3):610\u201328 e4. https:\/\/doi.org\/10.1016\/j.clinthera.2014.12.013.","DOI":"10.1016\/j.clinthera.2014.12.013"},{"issue":"11","key":"1010_CR17","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/jcph.955","volume":"57","author":"V Sahasrabudhe","year":"2017","unstructured":"Sahasrabudhe V, Terra SG, Hickman A, Saur D, Shi H, O\u2019Gorman M, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017;57(11):1432\u201343. https:\/\/doi.org\/10.1002\/jcph.955.","journal-title":"J Clin Pharmacol"},{"key":"1010_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"key":"1010_CR19","unstructured":"European Society of Cardiology Press Office: DAPA-CKD trial meets primary endpoint in patients with chronic kidney disease. 2020. https:\/\/www.escardio.org\/The-ESC\/Press-Office\/Press-releases\/DAPA. Accessed 8 Sep 2020."},{"key":"1010_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0406-8","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020. https:\/\/doi.org\/10.1038\/s41569-020-0406-8.","journal-title":"Nat Rev Cardiol."},{"key":"1010_CR21","doi-asserted-by":"publisher","unstructured":"Tuttle KR, Cherney DZ, Diabetic Kidney Disease Task Force of the American Society of N. Sodium glucose cotransporter 2 inhibition heralds a call-to-action for diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15(2):285\u20138. https:\/\/doi.org\/10.2215\/cjn.07730719.","DOI":"10.2215\/cjn.07730719"},{"issue":"11","key":"1010_CR22","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.2215\/CJN.05340419","volume":"14","author":"JJ Neumiller","year":"2019","unstructured":"Neumiller JJ, Kalyani RR. How does CREDENCE inform best use of SGLT2 inhibitors in CKD? Clin J Am Soc Nephrol. 2019;14(11):1667\u20139. https:\/\/doi.org\/10.2215\/CJN.05340419.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1010_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ahj.2018.08.016","volume":"206","author":"CP Cannon","year":"2018","unstructured":"Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11\u201323. https:\/\/doi.org\/10.1016\/j.ahj.2018.08.016.","journal-title":"Am Heart J"},{"issue":"2","key":"1010_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ndt\/gfz290","volume":"35","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transpl. 2020;35(2):274\u201382. https:\/\/doi.org\/10.1093\/ndt\/gfz290.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"1010_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137(2):119\u201329. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028268.","journal-title":"Circulation"},{"issue":"15","key":"1010_CR26","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","volume":"138","author":"BL Neuen","year":"2018","unstructured":"Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138(15):1537\u201350. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035901.","journal-title":"Circulation"},{"issue":"8","key":"1010_CR27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/dom.14041","volume":"22","author":"A Cahn","year":"2020","unstructured":"Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, et al. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab. 2020;22(8):1357\u201368. https:\/\/doi.org\/10.1111\/dom.14041.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1010_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1681\/ASN.2019111168","volume":"31","author":"MJ Jardine","year":"2020","unstructured":"Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020;31(5):1128\u201339. https:\/\/doi.org\/10.1681\/ASN.2019111168.","journal-title":"J Am Soc Nephrol"},{"key":"1010_CR29","unstructured":"Janssen Pharmaceuticals, Inc. Invokana (canagliflozin) tablets\u2014full prescribing information. 2020. http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVOKANA-pi.pdf. Accessed 11 Sep 2020."},{"key":"1010_CR30","unstructured":"Boehringer Ingelheim Pty Limited. Australian Product Information\u2014Jardiance empagliflozin film-coated tablets. 2020. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2014-PI-01783-1&d=202009211016933&d=202009221016933. Accessed 11 Sep 2020."},{"key":"1010_CR31","unstructured":"AstraZeneca Pty Ltd. Australian Product Information Forxiga. 2020. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2012-PI-02861-1&d=202009221016933. Accessed 11 Sep 2020."},{"key":"1010_CR32","unstructured":"Merck Sharp & Dohme (Australia) Pty Limited. Australian Product Information\u2014Steglatro (Ertugliflozin). 2019. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2018-PI-01724-1&d=202009221016933. Accessed 11 Sep 2020."},{"key":"1010_CR33","doi-asserted-by":"publisher","unstructured":"Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. infections in patients with diabetes mellitus. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8010076.","DOI":"10.3390\/jcm8010076"},{"issue":"3","key":"1010_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"S Geerlings","year":"2014","unstructured":"Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373\u201381. https:\/\/doi.org\/10.1016\/j.diabres.2013.12.052.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1010_CR35","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/dom.13959","volume":"22","author":"M Fralick","year":"2020","unstructured":"Fralick M, MacFadden DR. A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection. Diabetes Obes Metab. 2020;22(5):755\u20138. https:\/\/doi.org\/10.1111\/dom.13959.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1010_CR36","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu J, Li L, Li S, Jia P, Deng K, Chen W, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. https:\/\/doi.org\/10.1038\/s41598-017-02733-w.","journal-title":"Sci Rep."},{"issue":"2","key":"1010_CR37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13531","volume":"21","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(2):434\u20138. https:\/\/doi.org\/10.1111\/dom.13531.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1010_CR38","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1111\/dom.13820","volume":"21","author":"IC Lega","year":"2019","unstructured":"Lega IC, Bronskill SE, Campitelli MA, Guan J, Stall NM, Lam K, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019;21(11):2394\u2013404. https:\/\/doi.org\/10.1111\/dom.13820.","journal-title":"Diabetes Obes Metab"},{"key":"1010_CR39","doi-asserted-by":"publisher","unstructured":"McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020;8(1). https:\/\/doi.org\/10.1136\/bmjdrc-2020-001238.","DOI":"10.1136\/bmjdrc-2020-001238"},{"issue":"5","key":"1010_CR40","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237\u201350. https:\/\/doi.org\/10.1111\/dom.13648.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1010_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jchf.2018.11.013","volume":"7","author":"O Vardeny","year":"2019","unstructured":"Vardeny O, Vaduganathan M. Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. JACC Heart Fail. 2019;7(2):169\u201372. https:\/\/doi.org\/10.1016\/j.jchf.2018.11.013.","journal-title":"JACC Heart Fail."},{"issue":"10","key":"1010_CR42","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","volume":"61","author":"BC Lupsa","year":"2018","unstructured":"Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118\u201325. https:\/\/doi.org\/10.1007\/s00125-018-4663-6.","journal-title":"Diabetologia"},{"issue":"suppl 2","key":"1010_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.13611","volume":"21","author":"D Fitchett","year":"2019","unstructured":"Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab. 2019;21(suppl 2):34\u201342. https:\/\/doi.org\/10.1111\/dom.13611.","journal-title":"Diabetes Obes Metab"},{"key":"1010_CR44","unstructured":"U.S. Food and Drug Administration: FDA warns about the rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. 2018. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes. Accessed 18 Oct 2018."},{"issue":"11","key":"1010_CR45","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","volume":"170","author":"SJ Bersoff-Matcha","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764\u20139. https:\/\/doi.org\/10.7326\/M19-0085.","journal-title":"Ann Intern Med"},{"key":"1010_CR46","unstructured":"U.S. Food and Drug Administration: FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2015. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about. Accessed 13 July 2018."},{"issue":"1","key":"1010_CR47","doi-asserted-by":"publisher","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","volume":"9","author":"JR Donnan","year":"2019","unstructured":"Donnan JR, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019;9(1):e022577. https:\/\/doi.org\/10.1136\/bmjopen-2018-022577.","journal-title":"BMJ Open"},{"key":"1010_CR48","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstrom H, Melbye M, Eliasson B, Svensson AM, Franzen S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365.","journal-title":"BMJ"},{"key":"1010_CR49","unstructured":"Kumbhani DJ. Evaluation of Ertugliflozin Effcacy and Safety Cardiovascular Outcome Trial\u2014VERTIS CV. American College of Cardiology. 2020. https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2020\/06\/16\/11\/24\/vertis. Accessed 29 June 2020."},{"issue":"6","key":"1010_CR50","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc19-0093","volume":"42","author":"TAS Halden","year":"2019","unstructured":"Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care. 2019;42(6):1067\u201374. https:\/\/doi.org\/10.2337\/dc19-0093.","journal-title":"Diabetes Care"},{"issue":"1","key":"1010_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26(1):27\u201338. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.011.","journal-title":"Cell Metab"},{"issue":"2","key":"1010_CR52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499\u2013508. https:\/\/doi.org\/10.1172\/JCI72227.","journal-title":"J Clin Invest."},{"issue":"8","key":"1010_CR53","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783\u201394. https:\/\/doi.org\/10.1111\/dom.12670.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1010_CR54","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00228-019-02732-y","volume":"75","author":"TY Milder","year":"2019","unstructured":"Milder TY, Stocker SL, Samocha-Bonet D, Day RO, Greenfield JR. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease. Eur J Clin Pharmacol. 2019;75(11):1481\u201390. https:\/\/doi.org\/10.1007\/s00228-019-02732-y.","journal-title":"Eur J Clin Pharmacol"},{"key":"1010_CR55","unstructured":"U.S. Food and Drug Administration: FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). 2016. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin. Accessed 18 June 2018."},{"issue":"10166","key":"1010_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X.","journal-title":"Lancet"},{"issue":"11","key":"1010_CR57","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"suppl 1","key":"1010_CR58","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndt\/gfz230","volume":"35","author":"DZ Cherney","year":"2020","unstructured":"Cherney DZ, Kanbay M, Lovshin JA. Renal physiology of glucose handling and therapeutic implications. Nephrol Dial Transplant. 2020;35(suppl 1):i3\u201312. https:\/\/doi.org\/10.1093\/ndt\/gfz230.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1010_CR59","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587\u201397. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005081.","journal-title":"Circulation"},{"issue":"1","key":"1010_CR60","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97(1):202\u201312. https:\/\/doi.org\/10.1016\/j.kint.2019.09.013.","journal-title":"Kidney Int"},{"issue":"1","key":"1010_CR61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.kint.2019.09.023","volume":"97","author":"P Bjornstad","year":"2020","unstructured":"Bjornstad P, Nelson RG, Pavkov ME. Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes? Kidney Int. 2020;97(1):31\u20133. https:\/\/doi.org\/10.1016\/j.kint.2019.09.023.","journal-title":"Kidney Int"},{"issue":"2","key":"1010_CR62","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.kint.2019.02.033","volume":"96","author":"GJ Mayer","year":"2019","unstructured":"Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, et al. Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int. 2019;96(2):489\u2013504. https:\/\/doi.org\/10.1016\/j.kint.2019.02.033.","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"1010_CR63","doi-asserted-by":"publisher","first-page":"i48","DOI":"10.1093\/ndt\/gfz252","volume":"35","author":"BL Neuen","year":"2020","unstructured":"Neuen BL, Jardine MJ, Perkovic V. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Nephrol Dial Transplant. 2020;35(suppl 1):i48\u201355. https:\/\/doi.org\/10.1093\/ndt\/gfz252.","journal-title":"Nephrol Dial Transplant"},{"key":"1010_CR64","doi-asserted-by":"publisher","unstructured":"Triantafylidis LK, Hawley CE, Fagbote C, Li J, Genovese N, Paik JM. A pilot study embedding clinical pharmacists within an interprofessional nephrology clinic for the initiation and monitoring of empagliflozin in diabetic kidney disease. J Pharm Pract. 2019. https:\/\/doi.org\/10.1177\/0897190019876499.","DOI":"10.1177\/0897190019876499"},{"issue":"1","key":"1010_CR65","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1053\/j.ajkd.2020.01.015","volume":"76","author":"G Phadke","year":"2020","unstructured":"Phadke G, Kaushal A, Tolan DR, Hahn K, Jensen T, Bjornstad P, et al. Osmotic nephrosis and acute kidney injury associated with SGLT2 inhibitor use: a case report. Am J Kidney Dis. 2020;76(1):144\u20137. https:\/\/doi.org\/10.1053\/j.ajkd.2020.01.015.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1010_CR66","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.2337\/dc16-2200","volume":"40","author":"SN Heyman","year":"2017","unstructured":"Heyman SN, Khamaisi M, Rosen S, Rosenberger C, Abassi Z. Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media. Diabetes Care. 2017;40(4):e40\u20131. https:\/\/doi.org\/10.2337\/dc16-2200.","journal-title":"Diabetes Care"},{"issue":"6","key":"1010_CR67","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/imj.13442","volume":"47","author":"M Isaacs","year":"2017","unstructured":"Isaacs M, Tonks KT, Greenfield JR. Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors. Intern Med J. 2017;47(6):701\u20134. https:\/\/doi.org\/10.1111\/imj.13442.","journal-title":"Intern Med J."},{"issue":"4","key":"1010_CR68","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.2337\/dc17-1721","volume":"41","author":"EJ Meyer","year":"2018","unstructured":"Meyer EJ, Gabb G, Jesudason D. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian Spontaneous Adverse Event Notifications. Diabetes Care. 2018;41(4):e47\u20139. https:\/\/doi.org\/10.2337\/dc17-1721.","journal-title":"Diabetes Care"},{"issue":"8","key":"1010_CR69","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1210\/jc.2019-00139","volume":"104","author":"PS Hamblin","year":"2019","unstructured":"Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019;104(8):3077\u201387. https:\/\/doi.org\/10.1210\/jc.2019-00139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1010_CR70","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Y Handelsman","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22(6):753\u201362. https:\/\/doi.org\/10.4158\/EP161292.PS.","journal-title":"Endocr Pract."},{"issue":"1","key":"1010_CR71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/dom.13012","volume":"20","author":"BM Bonora","year":"2018","unstructured":"Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab. 2018;20(1):25\u201333. https:\/\/doi.org\/10.1111\/dom.13012.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1010_CR72","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190\u20135. https:\/\/doi.org\/10.2337\/db15-1356.","journal-title":"Diabetes"},{"issue":"5","key":"1010_CR73","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/dom.13224","volume":"20","author":"D Polidori","year":"2018","unstructured":"Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, Crawford PA. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab. 2018;20(5):1321\u20136. https:\/\/doi.org\/10.1111\/dom.13224.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1010_CR74","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/dom.13870","volume":"22","author":"E Ferrannini","year":"2020","unstructured":"Ferrannini E, Baldi S, Frias JP, Guja C, Hardy E, Repetto E, et al. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: the randomized, active-controlled DURATION-8 study. Diabetes Obes Metab. 2020;22(1):99\u2013106. https:\/\/doi.org\/10.1111\/dom.13870.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1010_CR75","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/dom.13890","volume":"22","author":"Y Sato","year":"2020","unstructured":"Sato Y, Nunoi K, Kaku K, Yoshida A, Suganami H. Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. Diabetes Obes Metab. 2020;22(2):222\u201330. https:\/\/doi.org\/10.1111\/dom.13890.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1010_CR76","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME Trial. Diabetes Care. 2018;41(1):e4\u20135. https:\/\/doi.org\/10.2337\/dc17-1551.","journal-title":"Diabetes Care"},{"issue":"6","key":"1010_CR77","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","volume":"62","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia. 2019;62(6):926\u201338. https:\/\/doi.org\/10.1007\/s00125-019-4839-8.","journal-title":"Diabetologia"},{"issue":"6","key":"1010_CR78","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00125-019-4835-z","volume":"62","author":"L Potier","year":"2019","unstructured":"Potier L, Roussel R, Velho G, Saulnier PJ, Bumbu A, Matar O, et al. Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. Diabetologia. 2019;62(6):939\u201347. https:\/\/doi.org\/10.1007\/s00125-019-4835-z.","journal-title":"Diabetologia"},{"issue":"6","key":"1010_CR79","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s00125-019-4861-x","volume":"62","author":"M Monteiro-Soares","year":"2019","unstructured":"Monteiro-Soares M, Ribeiro-Vaz I, Boyko EJ. Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation. Diabetologia. 2019;62(6):900\u20134. https:\/\/doi.org\/10.1007\/s00125-019-4861-x.","journal-title":"Diabetologia"},{"key":"1010_CR80","doi-asserted-by":"publisher","unstructured":"Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC et al. Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.99123.","DOI":"10.1172\/jci.insight.99123"},{"issue":"1","key":"1010_CR81","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2215\/CJN.04530418","volume":"14","author":"MA de Jong","year":"2019","unstructured":"de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, et al. Effects of dapagliflozin on circulating markers of phosphate homeostasis. Clin J Am Soc Nephrol. 2019;14(1):66\u201373. https:\/\/doi.org\/10.2215\/CJN.04530418.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1010_CR82","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MNH.0000000000000505","volume":"28","author":"JSJ Vinke","year":"2019","unstructured":"Vinke JSJ, Heerspink HJL, de Borst MH. Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus. Curr Opin Nephrol Hypertens. 2019;28(4):321\u20137. https:\/\/doi.org\/10.1097\/MNH.0000000000000505.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"1010_CR83","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2215\/CJN.13801118","volume":"14","author":"D Edmonston","year":"2019","unstructured":"Edmonston D, Wolf M. Good guys, bad guys, guesses, and near misses in nephrology. Clin J Am Soc Nephrol. 2019;14(1):7\u20139. https:\/\/doi.org\/10.2215\/CJN.13801118.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1010_CR84","doi-asserted-by":"publisher","first-page":"e3170","DOI":"10.1002\/dmrr.3170","volume":"35","author":"X Li","year":"2019","unstructured":"Li X, Li T, Cheng Y, Lu Y, Xue M, Xu L, et al. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis. Diabetes Metab Res Rev. 2019;35(7):e3170. https:\/\/doi.org\/10.1002\/dmrr.3170.","journal-title":"Diabetes Metab Res Rev."},{"issue":"5","key":"1010_CR85","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.diabet.2019.01.010","volume":"45","author":"L Cheng","year":"2019","unstructured":"Cheng L, Li YY, Hu W, Bai F, Hao HR, Yu WN, et al. Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diabetes Metab. 2019;45(5):436\u201345. https:\/\/doi.org\/10.1016\/j.diabet.2019.01.010.","journal-title":"Diabetes Metab."},{"issue":"1","key":"1010_CR86","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101(1):157\u201366. https:\/\/doi.org\/10.1210\/jc.2015-3167.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1010_CR87","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962\u201371. https:\/\/doi.org\/10.1038\/ki.2013.356.","journal-title":"Kidney Int"},{"issue":"10","key":"1010_CR88","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-019-04968-x","volume":"30","author":"K Hidayat","year":"2019","unstructured":"Hidayat K, Du X, Shi BM. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int. 2019;30(10):1923\u201340. https:\/\/doi.org\/10.1007\/s00198-019-04968-x.","journal-title":"Osteoporos Int"},{"key":"1010_CR89","doi-asserted-by":"publisher","unstructured":"Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.00547-2020.","DOI":"10.1183\/13993003.00547-2020"},{"key":"1010_CR90","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0941","author":"A Ceriello","year":"2020","unstructured":"Ceriello A, Standl E, Catrinoiu D, Itzhak B, Lalic NM, Rahelic D, et al. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. Diabetes Care. 2020. https:\/\/doi.org\/10.2337\/dc20-0941.","journal-title":"Diabetes Care"},{"issue":"6","key":"1010_CR91","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","volume":"8","author":"SR Bornstein","year":"2020","unstructured":"Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546\u201350. https:\/\/doi.org\/10.1016\/S2213-8587(20)30152-2.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"suppl 1","key":"1010_CR92","doi-asserted-by":"publisher","first-page":"i13","DOI":"10.1093\/ndt\/gfz237","volume":"35","author":"JL Gorriz","year":"2020","unstructured":"Gorriz JL, Navarro-Gonzalez JF, Ortiz A, Vergara A, Nunez J, Jacobs-Cacha C, et al. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrol Dial Transplant. 2020;35(suppl 1):i13\u201323. https:\/\/doi.org\/10.1093\/ndt\/gfz237.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1010_CR93","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1046\/j.1464-5491.2003.01025.x","volume":"20","author":"G Biesenbach","year":"2003","unstructured":"Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med. 2003;20(8):642\u20135. https:\/\/doi.org\/10.1046\/j.1464-5491.2003.01025.x.","journal-title":"Diabet Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-01010-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:09:54Z","timestamp":1744715394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-01010-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":93,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1010"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-01010-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"27 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TYM drafted the manuscript. TYM, SLS, ROD, and JRG edited and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}